Generic Name

Ibandronate

FDA approval date: March 19, 2012
Classification: Bisphosphonate
Form: Injection, Tablet

What is Ibandronate?

Ibandronate sodium injection is a bisphosphonate indicated for the treatment of osteoporosis in postmenopausal women.
Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

The Comparison of Ibandronate and Zoledronic Acid After Denosumab Discontinuation: A Randomized Non-inferiority Trial

Summary: This study is a prospective, multicenter, open-label, randomized non-inferiority trial comparing intravenous ibandronate and zoledronic acid as sequential therapy after denosumab discontinuation in postmenopausal women with osteoporosis. This trial primarily targets patients with short-term denosumab exposure (less than three years) and is conducted as a preliminary investigation. The findings are...